Clyde Biosciences Autumn Business Update
- CiPA 28 study finished and data submitted weeks ahead of schedule
- New CellOPTIQ®-X contractility assay launched
- New Heart Failure model launched
Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important planned strategic initiatives.
The CiPA initiative has the potential to reconfigure how cardiotoxicity is assessed. Clyde Biosciences has been involved in CiPA since its inception and its Chief Scientific Officer, Professor Godfrey Smith, co-leads the myocyte study group. The latest phase of the CiPA study was to capture data from 28 reference compounds on different platforms including Clyde’s CellOPTIQ®. The company can now report it has completed the study and has reported data to the FDA-led CiPA consortium ahead of schedule.
In the last three months, Clyde has launched two new assays. The first addresses critical needs among safety professionals for a novel contractility assay. Using Clyde’s trusted and validated platform the company has developed, tested and implemented a new algorithm which dramatically speeds up the acquisition, processing and reporting of data gathered to assess a compound’s effect on myocyte contraction. Response from our customers has been encouraging.
Out second new assay uses mammalian cells to perform measurements using our unique Power of 3 approach. Capturing voltage, calcium and contractility measurements in the same cells enables us to take a look at Exitation-Contraction Coupling, a critical measure in heart failure therapeutics. With great data already generated in that field, Clyde look forward to taking that assay to five out of the top 10 pharmaceutical companies over the next three months. No other single assay can provide such data.
Clyde continues to make progress against its strategic goal of replacing the current lengthy process of pre-IND drug screening. By gathering measurements of voltage, calcium and contractility earlier in the drug development process companies can reduce the liklihood of false positive and false negative results in their safety studies.